Allogenetics
Allogenetics provides a unique solution to the problem of organ rejection following transplantation.
$4.43M Seed ·
Led by NBank Capital · Source: biospace.com
Funding history ↓Signals
Website registeredDec 7, 2022 (3 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Seed | $4.43M | biospace.com |
Timeline
- Website created
Founders and team
CF
Constanca Figueiredo FounderPL
Phillipp Langrehr FounderRB
Rainer Blasczyk FounderOE
Oliver Ernst CEO and Managing DirectorJR
Jeroen Rovers Chief Medical Officer
Investors
Similar Health and bio companies
SSeawolf Therapeutics$100M Seed · Nov 2026
TTestDynamics$9M Series A · Nov 2026
IINFevo$15M Seed · Nov 2026
KKnit Health$35M Seed · Nov 2026
RRemedy Robotics$62M Series A · Nov 2026
VVumedi$140M Series B+ · Nov 2026
Other companies backed by NBank Capital
IInhalPlus$559.4K Pre Seed · Oct 2026
BBioweg$19M Series A · Sep 2025
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/allogenetics (get a free API key).